On March 29, 2017 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, reported that it will deliver a poster presentation at the 2017 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 1 – 5 in Washington, DC (Press release, Aeglea BioTherapeutics, MAR 29, 2017, View Source [SID1234518308]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Full abstracts are available online at www.aacr.org. Details of the poster presentation are listed below: Title: Reducing systemic arginine with arginase (AEB1102) therapy does not suppress the immune response induced by anti-PD-1 and anti-PD-L1, and exerts an additive anti-tumor and synergistic survival benefit

Abstract Number: 3964
Session Title: Tumor Microenvironment 5
Date: Tuesday, April 4
Presentation Time: 8 a.m. – 12 p.m. ET
Location: Walter E. Washington Convention Center, Halls A-C, Poster Section 42